The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

BACKGROUND: The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence (LR)-free survival (LRFS) following surgery for breast cancer in postmenopausal women. In addition, we examined whether EP may help tailor local the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzal, F, Filipits, M, Rudas, M, Greil, R, Dietze, O, Samonigg, H, Lax, S, Herz, W, Dubsky, P, Bartsch, R, Kronenwett, R, Gnant, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Genetics and Genomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402462/
https://www.ncbi.nlm.nih.gov/pubmed/25867274
http://dx.doi.org/10.1038/bjc.2015.98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402462/
https://www.ncbi.nlm.nih.gov/pubmed/25867274
http://dx.doi.org/10.1038/bjc.2015.98

Ejemplares similares